{"pmid":32433015,"title":"Delayed Laboratory Response to COVID-19 Caused by Molecular Diagnostic Contamination.","text":["Delayed Laboratory Response to COVID-19 Caused by Molecular Diagnostic Contamination.","The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) created an exceptional situation in which numerous laboratories in Europe simultaneously implemented SARS-CoV-2 diagnostics. These laboratories reported in February 2020 that commercial primer and probe batches for SARS-CoV-2 detection were contaminated with synthetic control material, causing delays of regional testing roll-out in various countries.","Emerg Infect Dis","Mogling, Ramona","Meijer, Adam","Berginc, Natasa","Bruisten, Sylvia","Charrel, Remi","Coutard, Bruno","Eckerle, Isabella","Enouf, Vincent","Hungnes, Olav","Korukluoglu, Gulay","Kossyvakis, Thanos","Mentis, Andreas","Molenkamp, Richard","Muradrasoli, Shaman","Papa, Anna","Pigny, Fiona","Thirion, Laurence","van der Werf, Sylvie","Reusken, Chantal","32433015"],"abstract":["The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) created an exceptional situation in which numerous laboratories in Europe simultaneously implemented SARS-CoV-2 diagnostics. These laboratories reported in February 2020 that commercial primer and probe batches for SARS-CoV-2 detection were contaminated with synthetic control material, causing delays of regional testing roll-out in various countries."],"journal":"Emerg Infect Dis","authors":["Mogling, Ramona","Meijer, Adam","Berginc, Natasa","Bruisten, Sylvia","Charrel, Remi","Coutard, Bruno","Eckerle, Isabella","Enouf, Vincent","Hungnes, Olav","Korukluoglu, Gulay","Kossyvakis, Thanos","Mentis, Andreas","Molenkamp, Richard","Muradrasoli, Shaman","Papa, Anna","Pigny, Fiona","Thirion, Laurence","van der Werf, Sylvie","Reusken, Chantal"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433015","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3201/eid2608.201843","keywords":["covid-19","europe","pcr","sars-cov-2","commercial nucleotide production","contamination","coronavirus disease","coronaviruses","delayed laboratory response","molecular diagnostics","primers","probes","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"topics":["Diagnosis"],"weight":1,"_version_":1667342288127262720,"score":9.490897,"similar":[{"pmid":32197059,"title":"Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe.","text":["Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe.","Early infections with severe acute respiratory syndrome coronavirus 2 in Europe were detected in travelers from Wuhan, China, in January 2020. In 1 tour group, 5 of 30 members were ill; 3 cases were laboratory confirmed. In addition, a healthcare worker was infected. This event documents early importation and subsequent spread of the virus in Europe.","Emerg Infect Dis","Olsen, Sonja J","Chen, Meng-Yu","Liu, Yu-Lun","Witschi, Mark","Ardoin, Alexis","Calba, Clementine","Mathieu, Pauline","Masserey, Virginie","Maraglino, Francesco","Marro, Stefano","Penttinen, Pasi","Robesyn, Emmanuel","Pukkila, Jukka","32197059"],"abstract":["Early infections with severe acute respiratory syndrome coronavirus 2 in Europe were detected in travelers from Wuhan, China, in January 2020. In 1 tour group, 5 of 30 members were ill; 3 cases were laboratory confirmed. In addition, a healthcare worker was infected. This event documents early importation and subsequent spread of the virus in Europe."],"journal":"Emerg Infect Dis","authors":["Olsen, Sonja J","Chen, Meng-Yu","Liu, Yu-Lun","Witschi, Mark","Ardoin, Alexis","Calba, Clementine","Mathieu, Pauline","Masserey, Virginie","Maraglino, Francesco","Marro, Stefano","Penttinen, Pasi","Robesyn, Emmanuel","Pukkila, Jukka"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32197059","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.3201/eid2607.200359","keywords":["2019 novel coronavirus disease","covid-19","europe","sars-cov-2","coronavirus","respiratory infections","severe acute respiratory syndrome coronavirus 2","transmission","travel-related illness","viruses","zoonoses"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission"],"weight":1,"_version_":1666138490070368256,"score":166.39938},{"pmid":32156330,"pmcid":"PMC7068163","title":"Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020.","text":["Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020.","The need for timely establishment of diagnostic assays arose when Germany was confronted with the first travel-associated outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Europe. We describe our laboratory experiences during a large contact tracing investigation, comparing previously published real-time RT-PCR assays in different PCR systems and a commercial kit. We found that assay performance using the same primers and probes with different PCR systems varied and the commercial kit performed well.","Euro Surveill","Konrad, Regina","Eberle, Ute","Dangel, Alexandra","Treis, Bianca","Berger, Anja","Bengs, Katja","Fingerle, Volker","Liebl, Bernhard","Ackermann, Nikolaus","Sing, Andreas","32156330"],"abstract":["The need for timely establishment of diagnostic assays arose when Germany was confronted with the first travel-associated outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Europe. We describe our laboratory experiences during a large contact tracing investigation, comparing previously published real-time RT-PCR assays in different PCR systems and a commercial kit. We found that assay performance using the same primers and probes with different PCR systems varied and the commercial kit performed well."],"journal":"Euro Surveill","authors":["Konrad, Regina","Eberle, Ute","Dangel, Alexandra","Treis, Bianca","Berger, Anja","Bengs, Katja","Fingerle, Volker","Liebl, Bernhard","Ackermann, Nikolaus","Sing, Andreas"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156330","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.2807/1560-7917.ES.2020.25.9.2000173","keywords":["covid-19","corona virus","infectious disease","laboratory diagnostics","molecular testing","real-time pcr","sars-cov-2","outbreaks"],"locations":["Germany","Bavaria, Germany"],"countries":["Germany"],"countries_codes":["DEU|Germany"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492685516800,"score":162.15074},{"pmid":32046815,"pmcid":"PMC7029448","title":"Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.","text":["Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.","Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers.","Euro Surveill","Reusken, Chantal B E M","Broberg, Eeva K","Haagmans, Bart","Meijer, Adam","Corman, Victor M","Papa, Anna","Charrel, Remi","Drosten, Christian","Koopmans, Marion","Leitmeyer, Katrin","On Behalf Of Evd-LabNet And Erli-Net","32046815"],"abstract":["Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers."],"journal":"Euro Surveill","authors":["Reusken, Chantal B E M","Broberg, Eeva K","Haagmans, Bart","Meijer, Adam","Corman, Victor M","Papa, Anna","Charrel, Remi","Drosten, Christian","Koopmans, Marion","Leitmeyer, Katrin","On Behalf Of Evd-LabNet And Erli-Net"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32046815","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.2807/1560-7917.ES.2020.25.6.2000082","keywords":["2019-ncov","coronavirus","emerging infections","laboratory","response","zoonoses"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493011623937,"score":160.8617},{"pmid":32267220,"title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","text":["Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.","Emerg Infect Dis","Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L","32267220"],"abstract":["A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies."],"journal":"Emerg Infect Dis","authors":["Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267220","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3201/eid2607.200841","keywords":["covid-19","elisa","hcov","rbd","sars-cov-2","severe acute respiratory syndrome coronavirus 2","antibodies","coronavirus","coronavirus disease 2019","human coronavirus","neutralization","nucleocapsid protein","receptor-binding domain","respiratory infections","serologic analysis","spike protein","viruses","zoonoses"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491931590658,"score":156.47247},{"pmid":32396505,"title":"US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.","text":["US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent associated with coronavirus disease, which emerged in late 2019. In response, we developed a diagnostic panel consisting of 3 real-time reverse transcription PCR assays targeting the nucleocapsid gene and evaluated use of these assays for detecting SARS-CoV-2 infection. All assays demonstrated a linear dynamic range of 8 orders of magnitude and an analytical limit of detection of 5 copies/reaction of quantified RNA transcripts and 1 x 10(-1.5) 50% tissue culture infectious dose/mL of cell-cultured SARS-CoV-2. All assays performed comparably with nasopharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. We obtained no false-positive amplifications with other human coronaviruses or common respiratory pathogens. Results from all 3 assays were highly correlated during clinical specimen testing. On February 4, 2020, the Food and Drug Administration issued an Emergency Use Authorization to enable emergency use of this panel.","Emerg Infect Dis","Lu, Xiaoyan","Wang, Lijuan","Sakthivel, Senthilkumar K","Whitaker, Brett","Murray, Janna","Kamili, Shifaq","Lynch, Brian","Malapati, Lakshmi","Burke, Stephen A","Harcourt, Jennifer","Tamin, Azaibi","Thornburg, Natalie J","Villanueva, Julie M","Lindstrom, Stephen","32396505"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent associated with coronavirus disease, which emerged in late 2019. In response, we developed a diagnostic panel consisting of 3 real-time reverse transcription PCR assays targeting the nucleocapsid gene and evaluated use of these assays for detecting SARS-CoV-2 infection. All assays demonstrated a linear dynamic range of 8 orders of magnitude and an analytical limit of detection of 5 copies/reaction of quantified RNA transcripts and 1 x 10(-1.5) 50% tissue culture infectious dose/mL of cell-cultured SARS-CoV-2. All assays performed comparably with nasopharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. We obtained no false-positive amplifications with other human coronaviruses or common respiratory pathogens. Results from all 3 assays were highly correlated during clinical specimen testing. On February 4, 2020, the Food and Drug Administration issued an Emergency Use Authorization to enable emergency use of this panel."],"journal":"Emerg Infect Dis","authors":["Lu, Xiaoyan","Wang, Lijuan","Sakthivel, Senthilkumar K","Whitaker, Brett","Murray, Janna","Kamili, Shifaq","Lynch, Brian","Malapati, Lakshmi","Burke, Stephen A","Harcourt, Jennifer","Tamin, Azaibi","Thornburg, Natalie J","Villanueva, Julie M","Lindstrom, Stephen"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396505","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3201/eid2608.201246","keywords":["2019 novel coronavirus disease","covid-19","sars-cov-2","coronavirus disease","real-time rt-pcr","real-time reverse transcription pcr","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666627827924992000,"score":153.3967}]}